Scarica l'app Stockscreener
1.84
2.13%
-0.04
Dopo l'orario di chiusura:
1.86
0.02
+1.09%
Elicio Therapeutics Inc Borsa (ELTX) Ultime notizie
Why Is ELTX Stock Falling Today? - Stocktwits
Elicio Therapeutics Is Maintained at Buy by B. Riley Securities - Moomoo
Elicio to present new pancreatic cancer trial data at ESMO - Investing.com
Elicio to present new pancreatic cancer trial data at ESMO By Investing.com - Investing.com Nigeria
A pancreatic cancer study missed its main goal. Elicio presents new analyses Oct. 23. - Stock Titan
B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating - marketscreener.com
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) dropped from S&P Global BMI Index - marketscreener.com
Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis - kalkine.com.au
Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines - The Globe and Mail
Elicio Therapeutics (NASDAQ: ELTX) Announces 2026 Annual Meeting Date and Submission Deadlines - Kalkine Media
Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer By Investing.com - Investing.com Nigeria
Elicio Therapeutics (ELTX) sets Sept. 24 cutoff for 2026 proxy proposals - stocktitan.net
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - stocktwits.com
Ladenburg Thalmann assumes Elicio Therapeutics at Buy, target $12 - scanx.trade
Pomerantz investigates Elicio Therapeutics after Phase 2 trial failure - scanx.trade
ELTX Stock Price, Quote & Chart - ChartMill
Elicio Therapeutics closes $15M registered direct offering - scanx.trade
Director at Elicio Therapeutics (ELTX) granted 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (NASDAQ: ELTX) receives 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) granted 21,750 options at $2.70 - stocktitan.net
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities - Moomoo
Elicio Therapeutics (ELTX) director gets 21,750 options at $2.70 - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 10-year stock option grant - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 options at $2.70 - stocktitan.net
Elicio Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - Quiver Quantitative
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
At Wells Fargo's health conference, Elicio plans one-on-one meetings - Stock Titan
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Schall Law investigates Elicio after Phase 2 trial failure - scanx.trade
HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings - MarketBeat
Elicio (ELTX) Financial Update: Reported EPS Misses Expectations for This Review; Reaction Snapshot: Shares Move Higher 2.98% in Latest TradingShare Dilution Risk - Vinanet
Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Hold Rating - Moomoo
Elicio Therapeutics (ELTX) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesBanking Earnings Report - Vinanet
ELTX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentEstimate Dispersion - Vinanet
Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics investigation follows Phase 2 failure - scanx.trade
Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com
Elicio Therapeutics added to Russell 2000, 3000 indexes - scanx.trade
Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade
Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat
Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elicio Therapeutics, Inc. (ELTX) Free Cash Flow 2025: $37.0M outflow, up 0.5% - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):